Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference
September 24, 2019 08:05 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 14, 2019 08:30 ET
|
Vaccinex, Inc.
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data...
Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer
August 13, 2019 08:05 ET
|
Vaccinex, Inc.
63% of evaluable subjects whose tumors had progressed during prior checkpoint inhibitor therapy benefited from treatment with the combination of pepinemab and avelumab Primary completion anticipated...
Vaccinex Announces $13.8 Million Private Placement
July 31, 2019 07:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 31, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting
June 03, 2019 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting
May 15, 2019 08:10 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s...
Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 15, 2019 08:05 ET
|
Vaccinex, Inc.
Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2019 Enrollment in Phase 2 SIGNAL Huntington’s...
Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
April 09, 2019 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
April 01, 2019 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 01, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex, Inc. to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 19, 2019
March 13, 2019 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 13, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...